Advanced gastric cancer remains one of the deadliest malignancies, with a 5-year overall survival rate below 10%. In recent years, combining chemotherapy with PD-1 or PD-L1 inhibitors has become standard first-line care for previously untreated HER2-negative disease. Yet major global trials and subgroup analyses have pointed to a recurring pattern: Asian patients often experience stronger … Read more
A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the U.S. The report comes from the laboratory of Stephanie Schmit, PhD, MPH, and was published in JAMA Network Open. It serves as an opportunity to better understand how … Read more
Researchers have discovered race-associated molecular differences in tumors that may impact the way patients with pancreatic cancer respond to immunotherapies. The findings, which were recently published in the American Association for Cancer Research (AACR) Journal, reinforce the need to include racially diverse participants in clinical studies. Immunotherapies are a type of cancer treatment that uses … Read more
The melding of visual information (microscopic and X-ray images, CT and MRI scans, for example) with text (exam notes, communications between physicians of varying specialties) is a key component of cancer care. But while artificial intelligence helps doctors review images and home in on disease-associated anomalies like abnormally shaped cells, it’s been difficult to develop … Read more